Well tolerated
across patients

Safety established in all doses1

Adverse reactions for QULIPTA™ and Placebo Adverse reactions for QULIPTA™ and Placebo Adverse reactions for QULIPTA™ and Placebo
ADVERSE REACTIONS
≥2% FOR QULIPTA AND GREATER THAN PLACEBO
Placebo (n=408) QULIPTA
10 mg QD (n=314)
QULIPTA
30 mg QD (n=411)
QULIPTA
60 mg QD (n=417)
Nausea 3% 5% 6% 9%
Constipation 1% 6% 6% 6%
Fatigue/Somnolence 3% 4% 4% 6%
Decreased appetite <1% 2% 1% 2%

QULIPTA IS A MIGRAINE PREVENTIVE WITH NO CONTRAINDICATIONS1

Study included patient populations with a history of gastrointestinal disorders (31%) or psychiatric disorders (43%). Mean age: 41 years, 88% female, 80% white, 17% black, 12% Hispanic or Latino. Study included patient populations with a history of gastrointestinal disorders (31%) or psychiatric disorders (43%). Mean age: 41 years, 88% female, 80% white, 17% black, 12% Hispanic or Latino. Study included patient populations with a history of gastrointestinal disorders (31%) or psychiatric disorders (43%). Mean age: 41 years, 88% female, 80% white, 17% black, 12% Hispanic or Latino.

A DECREASE IN WEIGHT WAS OBSERVED1

The proportion of patients with a weight decrease of at least 7% at any point was 4.9% for QULIPTA 60 mg, 3.2% for QULIPTA 30 mg, 3.8% for QULIPTA 10 mg, and 2.8% for placebo.1

SEE EFFICACY RESULTS